Ethris

About Ethris

Ethris GmbH, a clinical-stage biotechnology company headquartered in Planegg, Germany, is focused on developing messenger RNA (mRNA) based therapeutics to address severe respiratory diseases. The company was founded in 2009 by Dr. Carsten Rudolph and Professor Christian Plank, emerging from their academic research at Munich University. Dr. Rudolph's work in gene therapy for cystic fibrosis at the Department of Pediatrics at Ludwig Maximilian University of Munich, combined with Prof. Plank's expertise in drug delivery systems from the Technical University of Munich, formed the company's scientific foundation. Their shared vision was to overcome the limitations of traditional gene therapy by harnessing the potential of mRNA.

Ethris' business model centers on the discovery, design, and development of transcript therapies. The company generates revenue through strategic partnerships, technology licensing, and advancing its own pipeline of drug candidates. Its primary strategy involves out-licensing its assets, like the ETH47 asthma program, and forming product-development partnerships with mid- to large-sized pharmaceutical companies. Ethris has secured significant funding, totaling over $31.3 million across several rounds from investors including the Gates Foundation, Laureus Capital, and the European Union. The company collaborates with major industry players like Thermo Fisher Scientific to provide integrated mRNA manufacturing solutions and with Lonza to develop spray-dried, room-temperature stable mRNA vaccines.

The core of Ethris' operations is its proprietary technology suite, designed to overcome key challenges in mRNA therapeutics such as instability and immunogenicity. This includes the Stabilized Non-Immunogenic mRNA (SNIM® RNA) platform, which modifies mRNA molecules to make them less likely to trigger an immune response, allowing for repeated dosing. Complementing this is the Stabilized NanoParticle (SNaP LNP®) delivery platform, a lipidoid nanoparticle system optimized for protecting and transporting mRNA to target cells, particularly in the respiratory tract. A key feature of their technology is a stabilizer that prevents nanoparticle aggregation during nebulization, enabling efficient delivery via inhalation and nasal sprays. This innovation also allows for lyophilization and spray-drying, creating stable, dry powder formulations that may eliminate the need for cold-chain logistics.

The company's therapeutic pipeline is focused on respiratory diseases and protein replacement therapies. Its lead candidate, ETH47, is an intranasally administered mRNA therapy designed to treat uncontrolled, virus-induced asthma by encoding for interferon lambda (IFNλ), a protein that strengthens the airway's antiviral defenses. Having successfully completed a Phase 1 trial that demonstrated safety and local target engagement without systemic exposure, ETH47 advanced to a Phase 2a clinical trial in August 2025. Other pipeline programs target rare diseases like primary ciliary dyskinesia (PCD) and pulmonary alveolar proteinosis (PAP). Ethris is also developing mucosal vaccines to provide a localized immune response in the respiratory tract.